Assessment and Plan for Erythrocytosis
The initial assessment must distinguish between primary (polycythemia vera) and secondary erythrocytosis by first confirming true erythrocytosis, then systematically excluding secondary causes before pursuing JAK2 mutation testing.
Initial Assessment
Confirm True Erythrocytosis
- Hemoglobin thresholds: >18.5 g/dL in men, >16.5 g/dL in women 1
- Hematocrit thresholds: >49% in men, >48% in women 2
- Repeat testing to confirm elevation and review historical hemoglobin/hematocrit trends to distinguish longstanding from acquired erythrocytosis 3
- Rule out relative polycythemia from volume contraction (dehydration, diuretic use, chronic plasma volume loss) 4
Critical History Elements
- Age of onset: Young age or family history suggests congenital causes 3, 5
- Medication exposure: Testosterone, SGLT2 inhibitors, erythropoietin-stimulating agents 3, 4
- Cardiopulmonary symptoms: Chronic hypoxia from lung disease, sleep apnea, high altitude, cyanotic heart disease 6
- Smoking history: Carbon monoxide exposure
- Renal disease: Renal artery stenosis, polycystic kidney disease, renal tumors 3
- Associated symptoms: Pruritus, erythromelalgia, headache, visual disturbances suggest PV 4
Physical Examination Focus
- Splenomegaly (suggests PV or myeloproliferative neoplasm)
- Cyanosis (cardiopulmonary disease, congenital heart disease)
- Signs of hypoxia or cardiopulmonary disease
- Abdominal masses (renal tumors)
Diagnostic Algorithm
Step 1: Complete Blood Count with Differential
- Isolated erythrocytosis: Consider secondary or hereditary causes first 4
- Erythrocytosis + leukocytosis or thrombocytosis: Proceed directly to JAK2 testing 4
Step 2: Serum Erythropoietin Level
- Low EPO: Indicates primary erythrocytosis → JAK2 mutation testing 5, 2
- Normal or elevated EPO: Indicates secondary erythrocytosis → investigate underlying causes 5, 2
Step 3: JAK2 Mutation Testing (if indicated)
- Test exons 12-15 for JAK2 mutations 3
- If positive: Diagnose polycythemia vera using WHO criteria 1
- If negative with high suspicion: Consider bone marrow biopsy and expanded next-generation sequencing panel for hereditary erythrocytosis 3
Step 4: Secondary Cause Investigation (if EPO normal/elevated)
- Arterial oxygen saturation: Rule out hypoxemia
- Chest imaging: Evaluate cardiopulmonary disease
- Sleep study: If obstructive sleep apnea suspected
- Renal imaging: Ultrasound or CT for renal masses, cysts, or vascular abnormalities
- Carboxyhemoglobin level: If smoking history
- Review medications: Discontinue offending agents if possible
Step 5: Specialized Testing (if above negative)
- Hemoglobin electrophoresis: High oxygen-affinity hemoglobin variants 3
- P50 measurement: Oxygen dissociation curve abnormalities
- Genetic testing panel: For hereditary erythrocytosis (EPOR, HIF2A, PHD2, VHL, PIEZO1 mutations) 3
Management Plan
For Polycythemia Vera (JAK2-positive)
High-risk patients (age ≥60 years or prior thrombosis):
- Phlebotomy: Maintain hematocrit <45% 7
- Low-dose aspirin: 81-100 mg daily 7
- Cytoreductive therapy: Hydroxyurea or interferons 7
- Monitor every 3-6 months for thrombosis, bleeding, disease progression 7
Low-risk patients (age <60 years, no prior thrombosis):
For Secondary Erythrocytosis
Treat the underlying cause 2:
- Optimize cardiopulmonary disease management
- CPAP for sleep apnea
- Discontinue causative medications (testosterone, SGLT2 inhibitors)
- Surgical intervention for renal tumors or renal artery stenosis
- Smoking cessation
Phlebotomy considerations:
- No clear hematocrit target for secondary erythrocytosis 4
- Consider phlebotomy for symptom control (headache, hyperviscosity symptoms) 3
- Avoid routine phlebotomy without symptoms
Cardiovascular risk optimization:
- Low-dose aspirin may be considered 3
- Manage hypertension, hyperlipidemia, diabetes
For Cyanotic Congenital Heart Disease with Erythrocytosis
Most patients have compensated erythrocytosis requiring no intervention 6
Therapeutic phlebotomy indications (Class I recommendation):
- Hemoglobin >20 g/dL AND hematocrit >65% 6
- WITH symptoms of hyperviscosity (headache, fatigue, poor concentration) 6
- WITHOUT dehydration or iron deficiency 6
Phlebotomy technique:
- Remove 1 unit of blood with equal volume replacement (dextrose or saline) 6
Critical warning: Repeated routine phlebotomies are contraindicated (Class III) due to risk of iron depletion, decreased oxygen-carrying capacity, and stroke 6
Iron deficiency management:
- Confirm with peripheral blood smear and serum ferritin or transferrin saturation 6
- Oral iron supplementation with caution (monitor hemoglobin closely as rapid increase in red cell mass can occur) 6
- Discontinue when ferritin/transferrin saturation normalizes 6
- IV iron pulses if oral intolerance 6
For Idiopathic/JAK2-Unmutated Erythrocytosis
- Avoid cytoreductive therapy 3
- Phlebotomy for symptom control only 3
- Cardiovascular risk optimization 3
- Low-dose aspirin advised 3
- Consider expanded genetic testing if high clinical suspicion 3
Common Pitfalls
Aggressive phlebotomy in cyanotic heart disease: This is the most likely cause of complications, not hyperviscosity itself 6. Only phlebotomize when hemoglobin >20 g/dL, hematocrit >65%, AND symptomatic.
Assuming all erythrocytosis is PV: Secondary causes are more common than primary 2. Systematically exclude secondary causes before extensive myeloproliferative workup.
Ignoring medication-induced erythrocytosis: SGLT2 inhibitors and testosterone are increasingly recognized causes 3, 4.
Depleting iron stores: Iron deficiency in erythrocytosis increases stroke risk even with elevated hemoglobin 6. Monitor iron status and replace cautiously.
Missing hereditary causes in young patients: Family history and young age mandate genetic testing for congenital erythrocytosis 3, 5.